Page last updated: 2024-08-21

azomycin and Koch's Disease

azomycin has been researched along with Koch's Disease in 78 studies

Research

Studies (78)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	11 (14.10)	29.6817
2010's	44 (56.41)	24.3611
2020's	23 (29.49)	2.80

Authors

Authors	Studies
Andres, S; Bateson, A; Borroni, E; Cirillo, DM; Dippenaar, A; Feuerriegel, S; Ghodousi, A; Groenheit, R; Kohl, TA; Köser, CU; Kranzer, K; Machado, D; Maurer, FP; McHugh, TD; Merker, M; Niemann, S; Ortiz Canseco, J; Sirgel, F; Sun, E; Timm, J; Toro, JC; Utpatel, C; Viveiros, M; Warren, RM; Werngren, J; Wijkander, M; Witney, AA	1
Carr, W; Converse, PJ; Dartois, V; Dooley, KE; Garcia, A; Kurbatova, E; Nuermberger, EL; Stout, JE; Tasneen, R; Vernon, AA; Zimmerman, MD	1
Bresser, PL; Sathekge, MM; Vorster, M	1
Bagdasaryan, TR; Bateson, A; Borisov, S; Conradie, F; Crook, AM; Egizi, E; Everitt, D; Fabiane, SM; Foraida, S; Holsta, A; Howell, P; Hunt, R; Li, M; McHugh, TD; Mendel, CM; Mikiashvili, L; Ngubane, N; Olugbosi, M; Samoilova, A; Skornykova, S; Spigelman, M; Sun, E; Timm, J; Tudor, E; Tweed, CD; Variava, E; Wills, GH; Yablonskiy, P	1
Ashkin, D; Goswami, ND; Haley, CA	1
Bekele, F; Fekadu, G; Fetensa, G; Tolossa, T; Turi, E	1
Ang, CW; Avery, VM; Bernhardt, PV; Blaskovich, MAT; Bolisetti, R; Cooper, MA; Francisco, AF; Franzblau, SG; Hinton, AO; Jackson, CJ; Kelly, JM; Lee, BM; Sykes, ML; Tan, L; Wang, Y; West, NP	1
Lyons, MA	1
Nahid, P; Velásquez, GE	1
Aarnoutse, R; Andres, S; Choong, E; Decosterd, LA; Dreyer, V; John, A; Kalsdorf, B; Koehler, N; König, C; Krieger, D; Kuhns, M; Lange, C; Maurer, FP; Merker, M; Niemann, S; Peloquin, CA; Sanchez Carballo, PM; Schaub, D; Schön, T; Schönfeld, N; Verougstraete, N; Verstraete, AG; Werngren, J; Wicha, SG; Zur Wiesch, PA	1
Guo, T; Mehta, K; van der Graaf, PH; van Hasselt, JGC	1
Betoudji, F; Converse, PJ; Fotouhi, N; Lee, J; Li, SY; Mdluli, K; Nuermberger, EL; Upton, A	1
Alffenaar, JC; Anthony, RM; Nguyen, QH; Nguyen, TNT; Nguyen, TVA; Vu, DH	1
Chevula, J; Manga, V; Munnaluri, RK; Patnam, N; Yamini, L	1
Dheda, K; Dooley, KE; Furin, J; Gumbo, T; Maartens, G; Murray, M; Nardell, EA; Warren, RM	1
Cook-Scalise, S; Denkinger, CM; Dowdy, DW; Kendall, EA; Malhotra, S	1
Keam, SJ	1
Bendet, P; Berg, A; Cirrincione, K; Deshpande, D; Gumbo, T; Hanna, D; Hermann, D; Magombedze, G; Martin, K; Romero, K; Srivastava, S; van Zyl, J	1
Furin, J; McKenna, L	1
de Jong, BC; Decroo, T; Lynen, L; Piubello, A; Van Deun, A	1
Ekins, S; Kyaw Zin, PP; Makarov, V; Reynolds, RC; Salina, E	1
Bigelow, KM; Chang, YS; Dooley, KE; Nuermberger, EL; Tasneen, R	1
Showalter, HD	1
Bax, HI; de Steenwinkel, JEM; Keutzer, L; Pieterman, ED; Simonsson, USH; van den Berg, S; van der Meijden, A; Wang, H; Zimmerman, MD	1
Bacchetti, P; Dheda, K; Esmail, A; Gandhi, M; Gerona, R; Huo, S; Metcalfe, J; Reckers, A	1
Kashiyama, E; Kim, S; Masuda, M; Sasabe, H; Sasahara, K; Sasaki, T; Shibata, M; Takeuchi, K; Umehara, K	1
de Jong, BC; Decroo, T; Gils, T; Lynen, L; Van Deun, A	1
Anderson, RF; Blaser, A; Chatelain, E; Denny, WA; Franzblau, SG; Launay, D; Ma, Z; Maes, L; Palmer, BD; Shinde, SS; Thompson, AM; Wan, B; Wang, Y	1
Aarti, C; Barbabosa-Pliego, A; Khusro, A; Salem, AZM	1
Connell, N; Dartois, V; Freundlich, JS; Ho, HP; Inoyama, D; Kandasamy, S; Kumar, P; Occi, J; Paget, SD; Perryman, AL; Russo, R; Singleton, E; Tuckman, M; Zimmerman, MD	1
Borroni, E; Cirillo, DM; Crook, DW; Cugnata, F; Davies, TJ; Fowler, PW; Gibertoni Cruz, AL; Grazian, C; Hoosdally, SJ; Peto, TEA; Rancoita, PMV; Walker, TM	1
Akkerman, O; Al-Marzouqi, NH; Aleksa, A; Alffenaar, JW; Arias-Guillén, M; Belilovski, E; Bernal, E; Boeree, MJ; Borisov, SE; Bruchfeld, J; Cadiñanos Loidi, J; Cai, Q; Caminero, JA; Cebrian Gallardo, JJ; Centis, R; Codecasa, LR; D'Ambrosio, L; Dalcolmo, M; Danila, E; Dara, M; Davidavičienė, E; Davies Forsman, L; De Los Rios Jefe, J; Denholm, J; Duarte, R; Elamin, SE; Ferrarese, M; Filippov, A; Ganatra, S; Garcia, A; García-García, JM; Gayoso, R; Giraldo Montoya, AM; Gomez Rosso, RG; Gualano, G; Hoefsloot, W; Ilievska-Poposka, B; Jonsson, J; Khimova, E; Kuksa, L; Kunst, H; Laniado-Laborín, R; Li, Y; Magis-Escurra, C; Manfrin, V; Manga, S; Marchese, V; Martínez Robles, E; Maryandyshev, A; Matteelli, A; Migliori, GB; Mullerpattan, JB; Munoz-Torrico, M; Mustafa Hamdan, H; Nieto Marcos, M; Noordin, NM; Palmero, DJ; Palmieri, F; Payen, MC; Piubello, A; Pontali, E; Pontarelli, A; Quirós, S; Rendon, A; Skrahina, A; Šmite, A; Solovic, I; Sotgiu, G; Souleymane, MB; Spanevello, A; Stošić, M; Tadolini, M; Tiberi, S; Udwadia, ZF; van den Boom, M; Vescovo, M; Viggiani, P; Visca, D; Zhurkin, D; Zignol, M	1
Fattorini, L; Giannoni, F; Iacobino, A; Pardini, M; Piccaro, G	1
Schaberg, T	1
Burki, T	1
Jeong, BH; Koh, WJ; Kwon, YS	1
Bagcchi, S	1
Barry, CE; Blasco, F; Boshoff, HI; Cherian, J; Dick, T; Goh, A; Gurumurthy, M; Ho, PC; Jiricek, J; Lakshminarayana, SB; Manjunatha, UH; Nanjundappa, M; Nayyar, A; Ravindran, S; Singh, R	1
Cho, S; Franzblau, SG; Kim, Y; Lu, Y; Ma, Z; Mdluli, K; Upton, AM; Wang, B; Wang, Y; Xu, J; Yang, TJ	1
Amoabeng, O; Mdluli, KE; Minkowski, A; Nuermberger, EL; Tasneen, R; Upton, AM; Williams, K	1
Burger, DA; Dawson, R; Diacon, AH; Donald, PR; Everitt, D; Hutchings, J; Mendel, CM; Schall, R; Symons, G; van Niekerk, C; Venter, A; von Groote-Bidlingmaier, F	1
Blaser, A; Denny, WA; Franzblau, SG; Kmentova, I; Ma, Z; Palmer, BD; Sutherland, HS; Thompson, AM; Wan, B; Wang, Y	2
Grosset, J; Vernon, A	1
Bloemberg, GV; Böttger, EC; Hömke, R; Keller, PM; Ritter, C; Valsesia, G	1
Keum, YS; Park, SW; Patel, RV	1
Franzblau, SG; Gutka, HJ; Movahedzadeh, F; Wang, Y	1
Gonzalez-Martín, J; Hurtado, JC; López-Gavín, A; Tudó, G; Vergara, A	1
Bruhn, DF; Lee, RE; Lenaerts, AJ; Liu, J; Scherman, MS; Singh, AP; Yang, L	1
Ahmed, Z; Bhagat, A; Chandan, BK; Gupta, AP; Khullar, M; Kour, G; Munagala, G; Singh, PP; Vishwakarma, RA	1
Ahmed, Z; Bhagat, A; Kour, G; Kumar, A; Sharma, S; Singh, PP; Vishwakarma, RA	1
Dedicoat, M	1
Gao, F; Hu, M; Zheng, C	1
Berisio, R; Romano, M; Ruggiero, A; Squeglia, F	1
Nathan, C	1
Ahmad, Z; Derendorf, H; Ginsberg, A; Grosset, JH; Nuermberger, EL; Peloquin, CA; Singh, RP; Tyagi, S	1
Hutson, S	1
Barry, CE; Bollo, S; Boshoff, HI; Dowd, CS; Kang, S; Núñez-Vergara, LJ; Squella, JA; Zhang, L	1
Goldman, RC	1
Denny, WA; Palmer, BD	1
Degani, MS; Tawari, NR	1
Barry, CE; Boshoff, HI; Cherian, J; Choi, I; Dartois, V; Dick, T; Goodwin, M; Ha, YH; Jiricek, J; Keller, TH; Lakshminarayana, SB; Lee, YS; Manjunatha, UH; Mukherjee, T; Nayyar, A; Niyomrattanakit, P; Ravindran, S; Singh, R	1
Ginsberg, A	1
Bishai, WR; Davis, SL; Harper, J; Jain, SK; Kramnik, I; Nuermberger, EL; Pomper, MG; Skerry, C; Tasneen, R; Weir, M	1
Roehr, B	1
Amoabeng, O; Andries, K; Mdluli, KE; Minkowski, A; Nuermberger, EL; Peloquin, CA; Taylor, D; Wallis, RS; Williams, K	1
Chopra, S; Doppalapudi, RS; Franzblau, SG; Green, CE; Iyer, LV; Koolpe, GA; Madrid, PB; Matsuyama, KN; Riccio, ES; Ryan, KJ; Tambo-Ong, AA; Tran, TB; Wan, B	1
Kmietowicz, Z	1
Ahmad, K	1
Hashizume, H; Kawasaki, M; Komatsu, M; Matsumoto, M; Sasaki, H; Shimokawa, Y; Tomishige, T; Tsubouchi, H	1
Yeager, H	1
Aly, S; Andries, K; Basaraba, RJ; Cantarero, L; Ehlers, S; Hoff, D; Lenaerts, AJ; Orme, IM	1
Spigelman, MK	1
Nikitin, AV	1
Anderson, SW; Arain, TM; Baker, WR; Barry, CE; Kreiswirth, BN; Langhorne, MH; McMurray, DN; Sherman, DR; Stover, CK; Towell, JA; VanDevanter, DR; Warrener, P; Yuan, Y	1

Reviews

19 review(s) available for azomycin and Koch's Disease

Article	Year
Pretomanid development and its clinical roles in treating tuberculosis. Journal of global antimicrobial resistance, 2022, Volume: 31 Topics: Antitubercular Agents; Humans; Nitroimidazoles; Tuberculosis; Tuberculosis, Multidrug-Resistant	2022
Pretomanid resistance: An update on emergence, mechanisms and relevance for clinical practice. International journal of antimicrobial agents, 2023, Volume: 62, Issue:4 Topics: Animals; Antitubercular Agents; Mycobacterium tuberculosis; Nitroimidazoles; Tuberculosis; Tuberculosis, Multidrug-Resistant	2023
The Lancet Respiratory Medicine Commission: 2019 update: epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant and incurable tuberculosis. The Lancet. Respiratory medicine, 2019, Volume: 7, Issue:9 Topics: Antitubercular Agents; Diarylquinolines; Drug Therapy, Combination; Humans; Linezolid; Nitroimidazoles; Oxazoles; Periodicals as Topic; Pulmonary Medicine; Societies, Medical; Tuberculosis; Tuberculosis, Multidrug-Resistant	2019
Pretomanid: First Approval. Drugs, 2019, Volume: 79, Issue:16 Topics: Anti-Bacterial Agents; Antifungal Agents; Drug Approval; Humans; Nitroimidazoles; Tuberculosis; United States	2019
Molecule Property Analyses of Active Compounds for Journal of medicinal chemistry, 2020, 09-10, Volume: 63, Issue:17 Topics: Antitubercular Agents; Bacterial Proteins; Drug Discovery; Drug Resistance, Bacterial; Humans; Mycobacterium tuberculosis; Nitroimidazoles; Nucleoside-Phosphate Kinase; Structure-Activity Relationship; Tuberculosis	2020
Recent Progress in the Discovery and Development of 2-Nitroimidazooxazines and 6-Nitroimidazooxazoles to Treat Tuberculosis and Neglected Tropical Diseases. Molecules (Basel, Switzerland), 2020, Sep-10, Volume: 25, Issue:18 Topics: Antitubercular Agents; Chemistry Techniques, Synthetic; Drug Design; Drug Development; Humans; Mycobacterium tuberculosis; Nitroimidazoles; Structure-Activity Relationship; Tuberculosis	2020
Pretomanid for tuberculosis: a systematic review. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 2022, Volume: 28, Issue:1 Topics: Antitubercular Agents; Humans; Linezolid; Moxifloxacin; Nitroimidazoles; Pyrazinamide; Randomized Controlled Trials as Topic; Rifampin; Tuberculosis; Tuberculosis, Multidrug-Resistant	2022
Neoteric advancement in TB drugs and an overview on the anti-tubercular role of peptides through computational approaches. Microbial pathogenesis, 2018, Volume: 114 Topics: Antitubercular Agents; Computational Biology; Diarylquinolines; Drug Design; Extensively Drug-Resistant Tuberculosis; Humans; Models, Molecular; Mycobacterium tuberculosis; Nitroimidazoles; Oxazoles; Peptides; Tuberculosis; Tuberculosis, Multidrug-Resistant; World Health Organization	2018
[Tuberculosis: new treatment options and updated recommendations]. Deutsche medizinische Wochenschrift (1946), 2013, Volume: 138, Issue:14 Topics: Antitubercular Agents; Aza Compounds; Cross-Sectional Studies; Diagnosis, Differential; Diarylquinolines; Fluoroquinolones; Germany; Humans; Moxifloxacin; Nitroimidazoles; Oxazoles; Prognosis; Quinolines; Rifampin; Tuberculosis; Tuberculosis, Multidrug-Resistant	2013
Tuberculosis: clinical trials and new drug regimens. Current opinion in pulmonary medicine, 2014, Volume: 20, Issue:3 Topics: Acetamides; Adamantane; Antitubercular Agents; Clinical Trials as Topic; Diarylquinolines; Drug Administration Schedule; Drug Design; Ethylenediamines; Female; Fluoroquinolones; Humans; Levofloxacin; Linezolid; Male; Moxifloxacin; Nitroimidazoles; Oxazoles; Oxazolidinones; Spiro Compounds; Thiazines; Tuberculosis; Tuberculosis, Multidrug-Resistant	2014
Nitroimidazoles, Quinolones and Oxazolidinones as Fluorine Bearing Antitubercular Clinical Candidates. Mini reviews in medicinal chemistry, 2015, Volume: 15, Issue:14 Topics: Animals; Antitubercular Agents; Drug Discovery; Fluorine; Humans; Nitroimidazoles; Oxazolidinones; Quinolones; Tuberculosis	2015
Use of bedaquiline and delamanid in diabetes patients: clinical and pharmacological considerations. Drug design, development and therapy, 2016, Volume: 10 Topics: Aged; Animals; Antitubercular Agents; Arrhythmias, Cardiac; Comorbidity; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diarylquinolines; Drug Interactions; Drug Monitoring; Humans; Hypoglycemic Agents; Middle Aged; Nitroimidazoles; Oxazoles; Polypharmacy; Risk Assessment; Risk Factors; Tuberculosis	2016
Molecular Players in Tuberculosis Drug Development: Another Break in the Cell Wall. Current medicinal chemistry, 2017, Nov-24, Volume: 24, Issue:36 Topics: Antitubercular Agents; Benzothiazoles; Cell Wall; Drug Discovery; Humans; Molecular Docking Simulation; Mycobacterium tuberculosis; Nitroimidazoles; Rifampin; Tuberculosis	2017
The nitroimidazooxazines (PA-824 and analogs): structure-activity relationship and mechanistic studies. Future medicinal chemistry, 2010, Volume: 2, Issue:8 Topics: Animals; Antitubercular Agents; Humans; Mycobacterium tuberculosis; Nitroimidazoles; Structure-Activity Relationship; Tuberculosis	2010
New drugs and vaccines. Disease-a-month : DM, 2007, Volume: 53, Issue:1 Topics: Anti-Bacterial Agents; Drug Therapy, Combination; Fluoroquinolones; Humans; Mycobacterium bovis; Mycobacterium tuberculosis; Nitroimidazoles; Quinolones; Rifamycins; Tuberculosis; Tuberculosis Vaccines; World Health Organization	2007
New tuberculosis therapeutics: a growing pipeline. The Journal of infectious diseases, 2007, Aug-15, Volume: 196 Suppl 1 Topics: Adamantane; Animals; Antitubercular Agents; Clinical Trials as Topic; Diamines; Diarylquinolines; Ethylenediamines; Fluoroquinolones; Humans; Mice; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Nitroimidazoles; Quinolines; Tuberculosis	2007
[Prospects for design of novel antituberculosis drugs]. Antibiotiki i khimioterapiia = Antibiotics and chemoterapy [sic], 2006, Volume: 51, Issue:9-10 Topics: Animals; Antitubercular Agents; Cell Wall; Drug Design; Humans; Mycobacterium tuberculosis; Nitroimidazoles; Nucleic Acids; Protein Synthesis Inhibitors; Quinolines; Tuberculosis	2006
OPC-67683. Tuberculosis (Edinburgh, Scotland), 2008, Volume: 88, Issue:2 Topics: Animals; Antitubercular Agents; Humans; Nitroimidazoles; Oxazoles; Treatment Outcome; Tuberculosis	2008
PA-824. Tuberculosis (Edinburgh, Scotland), 2008, Volume: 88, Issue:2 Topics: Animals; Antitubercular Agents; Humans; Nitroimidazoles; Treatment Outcome; Tuberculosis	2008

Trials

2 trial(s) available for azomycin and Koch's Disease

Article	Year
Bedaquiline-Pretomanid-Linezolid Regimens for Drug-Resistant Tuberculosis. The New England journal of medicine, 2022, 09-01, Volume: 387, Issue:9 Topics: Aminoglycosides; Antitubercular Agents; Diarylquinolines; Fluoroquinolones; Humans; Linezolid; Nitroimidazoles; Rifampin; Risk Assessment; Treatment Outcome; Tuberculosis; Tuberculosis, Multidrug-Resistant	2022
Bactericidal activity of pyrazinamide and clofazimine alone and in combinations with pretomanid and bedaquiline. American journal of respiratory and critical care medicine, 2015, Apr-15, Volume: 191, Issue:8 Topics: Adult; Antitubercular Agents; Clofazimine; Diarylquinolines; Drug Therapy, Combination; Female; HIV Infections; Humans; Male; Nitroimidazoles; Pyrazinamide; Treatment Outcome; Tuberculosis; Tuberculosis, Multidrug-Resistant	2015

Article

Year

Bedaquiline-Pretomanid-Linezolid Regimens for Drug-Resistant Tuberculosis.

The New England journal of medicine, 2022, 09-01, Volume: 387, Issue:9

Topics: Aminoglycosides; Antitubercular Agents; Diarylquinolines; Fluoroquinolones; Humans; Linezolid; Nitroimidazoles; Rifampin; Risk Assessment; Treatment Outcome; Tuberculosis; Tuberculosis, Multidrug-Resistant

2022

Bactericidal activity of pyrazinamide and clofazimine alone and in combinations with pretomanid and bedaquiline.

American journal of respiratory and critical care medicine, 2015, Apr-15, Volume: 191, Issue:8

Topics: Adult; Antitubercular Agents; Clofazimine; Diarylquinolines; Drug Therapy, Combination; Female; HIV Infections; Humans; Male; Nitroimidazoles; Pyrazinamide; Treatment Outcome; Tuberculosis; Tuberculosis, Multidrug-Resistant

2015

Other Studies

57 other study(ies) available for azomycin and Koch's Disease

Article	Year
Ancient and recent differences in the intrinsic susceptibility of Mycobacterium tuberculosis complex to pretomanid. The Journal of antimicrobial chemotherapy, 2022, 05-29, Volume: 77, Issue:6 Topics: Antitubercular Agents; Humans; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Nitroimidazoles; Tuberculosis	2022
Novel Regimens of Bedaquiline-Pyrazinamide Combined with Moxifloxacin, Rifabutin, Delamanid and/or OPC-167832 in Murine Tuberculosis Models. Antimicrobial agents and chemotherapy, 2022, 04-19, Volume: 66, Issue:4 Topics: Animals; Antibiotics, Antitubercular; Antitubercular Agents; Diarylquinolines; Disease Models, Animal; Drug Administration Schedule; Drug Therapy, Combination; Isoniazid; Mice; Mice, Inbred BALB C; Moxifloxacin; Mycobacterium tuberculosis; Nitroimidazoles; Oxazoles; Pyrazinamide; Rifabutin; Tuberculosis	2022
PET/CT features of a novel gallium-68 labelled hypoxia seeking agent in patients diagnosed with tuberculosis: a proof-of-concept study. Nuclear medicine communications, 2022, Jul-01, Volume: 43, Issue:7 Topics: Gallium Radioisotopes; Humans; Hypoxia; Lung Diseases; Nitroimidazoles; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Radiopharmaceuticals; Tuberculosis	2022
Pretomanid in the Treatment of Patients with Tuberculosis in the United States. The New England journal of medicine, 2022, 09-01, Volume: 387, Issue:9 Topics: Antitubercular Agents; Humans; Mycobacterium tuberculosis; Nitroimidazoles; Tuberculosis; Tuberculosis, Multidrug-Resistant; United States	2022
Nitroimidazopyrazinones with Oral Activity against Tuberculosis and Chagas Disease in Mouse Models of Infection. Journal of medicinal chemistry, 2022, 10-13, Volume: 65, Issue:19 Topics: Animals; Chagas Disease; Disease Models, Animal; Mice; Mycobacterium tuberculosis; Nitroimidazoles; Nitroreductases; Trypanosoma cruzi; Tuberculosis	2022
Pharmacodynamics and Bactericidal Activity of Combination Regimens in Pulmonary Tuberculosis: Application to Bedaquiline-Pretomanid-Pyrazinamide. Antimicrobial agents and chemotherapy, 2022, 12-20, Volume: 66, Issue:12 Topics: Antitubercular Agents; Diarylquinolines; Humans; Nitroimidazoles; Pyrazinamide; Tuberculosis; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary	2022
Promise and Peril of Pretomanid-Rifamycin Regimens for Drug-susceptible Tuberculosis. American journal of respiratory and critical care medicine, 2023, 04-01, Volume: 207, Issue:7 Topics: Antitubercular Agents; Humans; Nitroimidazoles; Rifamycins; Tuberculosis	2023
Pretomanid-resistant tuberculosis. The Journal of infection, 2023, Volume: 86, Issue:5 Topics: Antitubercular Agents; Humans; Nitroimidazoles; Tuberculosis; Tuberculosis, Multidrug-Resistant	2023
Predictions of Bedaquiline and Pretomanid Target Attainment in Lung Lesions of Tuberculosis Patients using Translational Minimal Physiologically Based Pharmacokinetic Modeling. Clinical pharmacokinetics, 2023, Volume: 62, Issue:3 Topics: Animals; Antitubercular Agents; Humans; Lung; Mice; Nitroimidazoles; Pyrazinamide; Tuberculosis	2023
Next-Generation Diarylquinolines Improve Sterilizing Activity of Regimens with Pretomanid and the Novel Oxazolidinone TBI-223 in a Mouse Tuberculosis Model. Antimicrobial agents and chemotherapy, 2023, 04-18, Volume: 67, Issue:4 Topics: Animals; Antitubercular Agents; Diarylquinolines; Linezolid; Mice; Nitroimidazoles; Oxazolidinones; Tuberculosis; Tuberculosis, Multidrug-Resistant	2023
One-pot synthesis, spectral characterization, biological evaluation, molecular docking studies and in silico ADME/Tox profiling of new 2,4,5 triaryl imidazole derivatives as anti tubercular agents. The Indian journal of tuberculosis, 2023, Volume: 70, Issue:4 Topics: Antifungal Agents; Antitubercular Agents; Humans; Imidazoles; Microbial Sensitivity Tests; Molecular Docking Simulation; Mycobacterium tuberculosis; Nitroimidazoles; Structure-Activity Relationship; Tuberculosis	2023
Estimating the impact of a novel drug regimen for treatment of tuberculosis: a modeling analysis of projected patient outcomes and epidemiological considerations. BMC infectious diseases, 2019, Sep-09, Volume: 19, Issue:1 Topics: Adult; Antitubercular Agents; Diarylquinolines; Humans; Markov Chains; Nitroimidazoles; Prevalence; Pyrazinamide; Rifampin; South Africa; Treatment Outcome; Tuberculosis; Tuberculosis, Multidrug-Resistant	2019
Duration of pretomanid/moxifloxacin/pyrazinamide therapy compared with standard therapy based on time-to-extinction mathematics. The Journal of antimicrobial chemotherapy, 2020, 02-01, Volume: 75, Issue:2 Topics: Antitubercular Agents; Drug Therapy, Combination; Humans; Mathematics; Moxifloxacin; Mycobacterium tuberculosis; Nitroimidazoles; Pyrazinamide; Tuberculosis	2020
Are pretomanid-containing regimens for tuberculosis a victory or a victory narrative? The Lancet. Respiratory medicine, 2019, Volume: 7, Issue:12 Topics: Diarylquinolines; Humans; Moxifloxacin; Nitroimidazoles; Pyrazinamide; Tuberculosis; Tuberculosis, Pulmonary	2019
Tuberculosis treatment: one-shot approach or cascade of regimens? The Lancet. Respiratory medicine, 2020, Volume: 8, Issue:2 Topics: Diarylquinolines; Humans; Moxifloxacin; Nitroimidazoles; Pyrazinamide; Tuberculosis; Tuberculosis, Pulmonary	2020
Preserved Efficacy and Reduced Toxicity with Intermittent Linezolid Dosing in Combination with Bedaquiline and Pretomanid in a Murine Tuberculosis Model. Antimicrobial agents and chemotherapy, 2020, 09-21, Volume: 64, Issue:10 Topics: Animals; Antitubercular Agents; Diarylquinolines; Linezolid; Mice; Mice, Inbred BALB C; Mycobacterium tuberculosis; Nitroimidazoles; Tuberculosis; Tuberculosis, Multidrug-Resistant	2020
Superior Efficacy of a Bedaquiline, Delamanid, and Linezolid Combination Regimen in a Mouse Tuberculosis Model. The Journal of infectious diseases, 2021, 09-17, Volume: 224, Issue:6 Topics: Animals; Antitubercular Agents; Diarylquinolines; Disease Models, Animal; Drug Therapy, Combination; Linezolid; Mice; Mycobacterium tuberculosis; Nitroimidazoles; Oxazoles; Pyrazinamide; Recurrence; Tuberculosis	2021
Development and validation of a liquid chromatography-tandem mass spectrometry method for quantifying delamanid and its metabolite in small hair samples. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2021, Apr-15, Volume: 1169 Topics: Chromatography, Liquid; Hair; Humans; Limit of Detection; Linear Models; Nitroimidazoles; Oxazoles; Reproducibility of Results; Tandem Mass Spectrometry; Tuberculosis; Tuberculosis, Multidrug-Resistant	2021
Prediction of Human Pharmacokinetic Profiles of the Antituberculosis Drug Delamanid from Nonclinical Data: Potential Therapeutic Value against Extrapulmonary Tuberculosis. Antimicrobial agents and chemotherapy, 2021, 07-16, Volume: 65, Issue:8 Topics: Animals; Antitubercular Agents; Dogs; Humans; Mice; Models, Biological; Nitroimidazoles; Oxazoles; Rats; Tuberculosis	2021
6-Nitro-2,3-dihydroimidazo[2,1-b][1,3]thiazoles: Facile synthesis and comparative appraisal against tuberculosis and neglected tropical diseases. Bioorganic & medicinal chemistry letters, 2017, 06-01, Volume: 27, Issue:11 Topics: Animals; Antitubercular Agents; Chagas Disease; Disease Models, Animal; Mice; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Nitroimidazoles; Oxazoles; Structure-Activity Relationship; Thiazoles; Tuberculosis	2017
Novel Pyrimidines as Antitubercular Agents. Antimicrobial agents and chemotherapy, 2018, Volume: 62, Issue:3 Topics: Animals; Antitubercular Agents; Disease Models, Animal; Drug Design; Drug Stability; Female; Humans; Mice; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Nitroimidazoles; Pyrimidines; Solubility; Structure-Activity Relationship; Tuberculosis	2018
Validating a 14-Drug Microtiter Plate Containing Bedaquiline and Delamanid for Large-Scale Research Susceptibility Testing of Mycobacterium tuberculosis. Antimicrobial agents and chemotherapy, 2018, Volume: 62, Issue:9 Topics: Antitubercular Agents; Clofazimine; Diarylquinolines; Drug Resistance, Multiple, Bacterial; Humans; Linezolid; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Nitroimidazoles; Oxazoles; Reproducibility of Results; Tuberculosis; Tuberculosis, Multidrug-Resistant	2018
Surveillance of adverse events in the treatment of drug-resistant tuberculosis: A global feasibility study. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 2019, Volume: 83 Topics: Antitubercular Agents; Diarylquinolines; Drug Therapy, Combination; Feasibility Studies; Female; Humans; Male; Nitroimidazoles; Oxazoles; Pilot Projects; Tuberculosis; Tuberculosis, Multidrug-Resistant; World Health Organization	2019
The Combination Rifampin-Nitazoxanide, but Not Rifampin-Isoniazid-Pyrazinamide-Ethambutol, Kills Dormant Mycobacterium tuberculosis in Hypoxia at Neutral pH. Antimicrobial agents and chemotherapy, 2019, Volume: 63, Issue:7 Topics: Antitubercular Agents; Drug Combinations; Drug Therapy, Combination; Ethambutol; Humans; Hydrogen-Ion Concentration; Hypoxia; Isoniazid; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Nitroimidazoles; Oxazolidinones; Pyrazinamide; Rifampin; Tuberculosis	2019
Improving the health of the tuberculosis drug pipeline. The Lancet. Infectious diseases, 2014, Volume: 14, Issue:2 Topics: Antitubercular Agents; Clinical Trials as Topic; Diarylquinolines; Drug Approval; Drug Discovery; Global Health; Humans; Nitroimidazoles; Oxazoles; Research Support as Topic; Tuberculosis	2014
Novel drug combination for tuberculosis to be tested across 50 sites. BMJ (Clinical research ed.), 2014, May-27, Volume: 348 Topics: Antitubercular Agents; Aza Compounds; Clinical Trials, Phase II as Topic; Drug Therapy, Combination; Fluoroquinolones; Humans; Moxifloxacin; Nitroimidazoles; Pyrazinamide; Quinolines; Tuberculosis	2014
Pharmacokinetics-pharmacodynamics analysis of bicyclic 4-nitroimidazole analogs in a murine model of tuberculosis. PloS one, 2014, Volume: 9, Issue:8 Topics: Animals; Caco-2 Cells; Cell Line, Tumor; Disease Models, Animal; Female; Humans; Mice; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Nitroimidazoles; Retrospective Studies; Tuberculosis	2014
In vitro and in vivo activities of the nitroimidazole TBA-354 against Mycobacterium tuberculosis. Antimicrobial agents and chemotherapy, 2015, Volume: 59, Issue:1 Topics: Animals; Antitubercular Agents; Caco-2 Cells; Cell Line, Tumor; Disease Models, Animal; Drug Interactions; Drug Resistance, Bacterial; Female; Humans; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Nitroimidazoles; Oxazines; Oxazoles; Tuberculosis	2015
Contribution of the nitroimidazoles PA-824 and TBA-354 to the activity of novel regimens in murine models of tuberculosis. Antimicrobial agents and chemotherapy, 2015, Volume: 59, Issue:1 Topics: Animals; Antitubercular Agents; Clofazimine; Diarylquinolines; Disease Models, Animal; Drug Therapy, Combination; Female; Fluoroquinolones; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Nitroimidazoles; Oxazines; Oxazoles; Pyrazinamide; Random Allocation; Tuberculosis	2015
Synthesis and structure-activity relationships for extended side chain analogues of the antitubercular drug (6S)-2-nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine (PA-824). Journal of medicinal chemistry, 2015, Apr-09, Volume: 58, Issue:7 Topics: Administration, Oral; Animals; Antitubercular Agents; Biological Availability; Chemistry Techniques, Synthetic; Chronic Disease; Disease Models, Animal; Humans; Male; Mice, Inbred BALB C; Mice, Inbred Strains; Microbial Sensitivity Tests; Microsomes, Liver; Mycobacterium tuberculosis; Nitroimidazoles; Oxazoles; Rats, Sprague-Dawley; Structure-Activity Relationship; Tuberculosis	2015
A reader's guide to the bactericidal activity of pyrazinamide and clofazimine alone and in combinations with pretomanid and bedaquiline. American journal of respiratory and critical care medicine, 2015, Apr-15, Volume: 191, Issue:8 Topics: Clofazimine; Diarylquinolines; Female; HIV Infections; Humans; Male; Nitroimidazoles; Pyrazinamide; Tuberculosis	2015
Determination of MIC distribution and epidemiological cutoff values for bedaquiline and delamanid in Mycobacterium tuberculosis using the MGIT 960 system equipped with TB eXiST. Antimicrobial agents and chemotherapy, 2015, Volume: 59, Issue:7 Topics: Antitubercular Agents; Diarylquinolines; Humans; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Nitroimidazoles; Oxazoles; Reference Values; Tuberculosis; Tuberculosis, Multidrug-Resistant	2015
glpx Gene in Mycobacterium tuberculosis Is Required for In Vitro Gluconeogenic Growth and In Vivo Survival. PloS one, 2015, Volume: 10, Issue:9 Topics: Animals; Anti-Bacterial Agents; Bacterial Proteins; Carbon; Fatty Acids; Fructose-Bisphosphatase; Gene Deletion; Genes, Bacterial; Gluconeogenesis; Mice, Inbred BALB C; Microbial Sensitivity Tests; Microbial Viability; Mycobacterium tuberculosis; Nitroimidazoles; Stress, Physiological; Tuberculosis	2015
In vitro activity against Mycobacterium tuberculosis of levofloxacin, moxifloxacin and UB-8902 in combination with clofazimine and pretomanid. International journal of antimicrobial agents, 2015, Volume: 46, Issue:5 Topics: Antitubercular Agents; Clofazimine; Drug Interactions; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Nitroimidazoles; Tuberculosis	2015
Synthesis and evaluation of pretomanid (PA-824) oxazolidinone hybrids. Bioorganic & medicinal chemistry letters, 2016, Jan-15, Volume: 26, Issue:2 Topics: Animals; Antitubercular Agents; Chronic Disease; Disease Models, Animal; Mice; Mice, Inbred C57BL; Mycobacterium tuberculosis; Nitroimidazoles; Oxazolidinones; Tuberculosis	2016
Development and validation of a highly sensitive LC-MS/MS-ESI method for quantification of IIIM-019-A novel nitroimidazole derivative with promising action against Tuberculosis: Application to drug development. Journal of pharmaceutical and biomedical analysis, 2016, May-30, Volume: 124 Topics: Animals; Antitubercular Agents; Chromatography, Liquid; Drug Design; Limit of Detection; Microsomes, Liver; Nitroimidazoles; Rats; Spectrometry, Mass, Electrospray Ionization; Tuberculosis	2016
Preclinical comprehensive physicochemical and pharmacokinetic profiling of novel nitroimidazole derivative IIIM-019 - A potential oral treatment for tuberculosis. Pulmonary pharmacology & therapeutics, 2016, Volume: 40 Topics: Administration, Oral; Animals; Antitubercular Agents; Area Under Curve; Biological Availability; Caco-2 Cells; Chromatography, Liquid; Dose-Response Relationship, Drug; Half-Life; Humans; Male; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Microsomes, Liver; Mycobacterium tuberculosis; Nitroimidazoles; Oxazoles; Rats; Rats, Wistar; Solubility; Tandem Mass Spectrometry; Tuberculosis	2016
Using bedaquiline and delamanid in combination and safely. The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 2016, Volume: 20, Issue:10 Topics: Antitubercular Agents; Diarylquinolines; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Global Health; Humans; Nitroimidazoles; Oxazoles; Tuberculosis	2016
Microbiology. An antibiotic mimics immunity. Science (New York, N.Y.), 2008, Nov-28, Volume: 322, Issue:5906 Topics: Anaerobiosis; Antitubercular Agents; Glucosephosphate Dehydrogenase; Humans; Mycobacterium tuberculosis; Nitric Oxide; Nitroimidazoles; Nitroreductases; Reactive Nitrogen Species; Riboflavin; Tuberculosis	2008
PA-824 exhibits time-dependent activity in a murine model of tuberculosis. Antimicrobial agents and chemotherapy, 2011, Volume: 55, Issue:1 Topics: Animals; Antitubercular Agents; Female; Humans; Mice; Nitroimidazoles; Tuberculosis	2011
Synthesis and structure-activity relationships of aza- and diazabiphenyl analogues of the antitubercular drug (6S)-2-nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine (PA-824). Journal of medicinal chemistry, 2010, Dec-09, Volume: 53, Issue:23 Topics: Animals; Antitubercular Agents; Disease Models, Animal; Magnetic Resonance Spectroscopy; Male; Mice; Mice, Inbred BALB C; Nitroimidazoles; Oxazines; Rats; Rats, Sprague-Dawley; Structure-Activity Relationship; Tuberculosis	2010
Half-century-old TB drugs get a facelift in new cocktails. Nature medicine, 2010, Volume: 16, Issue:12 Topics: Antitubercular Agents; Aza Compounds; Clinical Trials as Topic; Drug Discovery; Drug Therapy, Combination; Fluoroquinolones; Humans; Moxifloxacin; Nitroimidazoles; Pyrazinamide; Quinolines; Tuberculosis	2010
The effect of 5-substitution on the electrochemical behavior and antitubercular activity of PA-824. Bioorganic & medicinal chemistry letters, 2011, Jan-15, Volume: 21, Issue:2 Topics: Antitubercular Agents; Electrochemistry; Humans; Mycobacterium tuberculosis; Nitroimidazoles; Oxidation-Reduction; Tuberculosis	2011
Maximizing bactericidal activity with combinations of bioreduced drugs. Future medicinal chemistry, 2010, Volume: 2, Issue:8 Topics: Animals; Antitubercular Agents; Clinical Trials as Topic; Drug Combinations; Drug Discovery; Free Radicals; Humans; Mycobacterium tuberculosis; Nitrofurans; Nitroimidazoles; Oxidation-Reduction; Quinoxalines; Tuberculosis	2010
Pharmacophore modeling and density functional theory analysis for a series of nitroimidazole compounds with antitubercular activity. Chemical biology & drug design, 2011, Volume: 78, Issue:3 Topics: Antitubercular Agents; Drug Design; Humans; Models, Biological; Models, Molecular; Mycobacterium tuberculosis; Nitroimidazoles; Quantitative Structure-Activity Relationship; Quantum Theory; Tuberculosis	2011
Structure-activity relationships of antitubercular nitroimidazoles. 3. Exploration of the linker and lipophilic tail of ((s)-2-nitro-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazin-6-yl)-(4-trifluoromethoxybenzyl)amine (6-amino PA-824). Journal of medicinal chemistry, 2011, Aug-25, Volume: 54, Issue:16 Topics: Animals; Antitubercular Agents; Bacterial Proteins; Drug Evaluation, Preclinical; Humans; Kinetics; Metabolic Clearance Rate; Mice; Microbial Sensitivity Tests; Microsomes, Liver; Molecular Structure; Mycobacterium tuberculosis; Nitroimidazoles; Nitroreductases; Prodrugs; Structure-Activity Relationship; Substrate Specificity; Tuberculosis	2011
The TB Alliance: overcoming challenges to chart the future course of TB drug development. Future medicinal chemistry, 2011, Volume: 3, Issue:10 Topics: Antitubercular Agents; Aza Compounds; Clinical Trials as Topic; Diarylquinolines; Drug Evaluation, Preclinical; Fluoroquinolones; Humans; Models, Organizational; Moxifloxacin; Nitroimidazoles; Quinolines; Tuberculosis	2011
Mouse model of necrotic tuberculosis granulomas develops hypoxic lesions. The Journal of infectious diseases, 2012, Feb-15, Volume: 205, Issue:4 Topics: Animals; Antitubercular Agents; Aza Compounds; Disease Models, Animal; Fluoroquinolones; Gene Expression Profiling; Genes, Bacterial; Granuloma; Hypoxia; Immunohistochemistry; Male; Mice; Mice, Inbred C3H; Moxifloxacin; Mycobacterium tuberculosis; Nitroimidazoles; Positron-Emission Tomography; Pyrazinamide; Quinolines; Treatment Outcome; Tuberculosis	2012
Trial tests new combination of drugs to treat tuberculosis. BMJ (Clinical research ed.), 2012, Mar-20, Volume: 344 Topics: AIDS-Related Opportunistic Infections; Antitubercular Agents; Aza Compounds; Clinical Trials as Topic; Drug Administration Schedule; Drug Resistance, Bacterial; Drug Therapy, Combination; Fluoroquinolones; Humans; Moxifloxacin; Mycobacterium tuberculosis; Nitroimidazoles; Pyrazinamide; Quinolines; Research Support as Topic; Tuberculosis; United States	2012
Sterilizing activities of novel combinations lacking first- and second-line drugs in a murine model of tuberculosis. Antimicrobial agents and chemotherapy, 2012, Volume: 56, Issue:6 Topics: Animals; Antitubercular Agents; Drug Therapy, Combination; Female; Isoniazid; Mice; Mice, Inbred BALB C; Mycobacterium tuberculosis; Nitroimidazoles; Oxazolidinones; Pyrazinamide; Rifampin; Tuberculosis; Tuberculosis, Multidrug-Resistant	2012
Discovery and optimization of benzotriazine di-N-oxides targeting replicating and nonreplicating Mycobacterium tuberculosis. Journal of medicinal chemistry, 2012, Jul-12, Volume: 55, Issue:13 Topics: Animals; Antitubercular Agents; Chlorocebus aethiops; Drug Discovery; Female; Isomerism; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Molecular Structure; Mycobacterium tuberculosis; Nitrofurans; Nitroimidazoles; Oxides; Quinoxalines; Rats; Tirapazamine; Triazines; Tuberculosis; Vero Cells	2012
New drug combination for TB is tested in unique trial. BMJ (Clinical research ed.), 2012, Jul-25, Volume: 345 Topics: Antitubercular Agents; Aza Compounds; Clinical Trials as Topic; Drug Combinations; Fluoroquinolones; Humans; Moxifloxacin; Nitroimidazoles; Pyrazinamide; Quinolines; Tuberculosis	2012
Tuberculosis: new drug class investigated through public-private partnership. AIDS treatment news, 2000, Jul-07, Issue:346 Topics: Antitubercular Agents; Cooperative Behavior; Humans; Nitroimidazoles; Private Sector; Public Sector; Tuberculosis	2000
New tuberculosis drug enters human trials. The Lancet. Infectious diseases, 2005, Volume: 5, Issue:8 Topics: Antitubercular Agents; Clinical Trials as Topic; Humans; Nitroimidazoles; Tuberculosis	2005
OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice. PLoS medicine, 2006, Volume: 3, Issue:11 Topics: Animals; Antitubercular Agents; Blood; Cell Line; Humans; In Vitro Techniques; Intracellular Membranes; Macrophages; Mammals; Mice; Microbial Sensitivity Tests; Microsomes, Liver; Mycobacterium; Mycobacterium bovis; Mycolic Acids; Nitroimidazoles; Oxazoles; Treatment Outcome; Tuberculosis	2006
Location of persisting mycobacteria in a Guinea pig model of tuberculosis revealed by r207910. Antimicrobial agents and chemotherapy, 2007, Volume: 51, Issue:9 Topics: Animals; Antibiotics, Antitubercular; Antitubercular Agents; Colony Count, Microbial; Diarylquinolines; Female; Granuloma; Guinea Pigs; Hypoxia; Isoniazid; Lung; Mycobacterium tuberculosis; Nitroimidazoles; Pyrazinamide; Quinolines; Radiation-Sensitizing Agents; Rifampin; Spleen; Tuberculosis	2007
A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. Nature, 2000, Jun-22, Volume: 405, Issue:6789 Topics: Animals; Antitubercular Agents; Bacterial Proteins; Drug Resistance, Microbial; Drug Resistance, Multiple; Guinea Pigs; Lipids; Metronidazole; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Nitroimidazoles; Oxazoles; Structure-Activity Relationship; Tuberculosis	2000